Standout Papers

Renal cell carcino... 1980 2026 1995 2010 1.7k
  1. Renal cell carcinoma (2017)
    James J. Hsieh, Mark P. Purdue et al. Nature Reviews Disease Primers
  2. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2017)
    John B.A.G. Haanen, Franck Carbonnel et al. Annals of Oncology
  3. Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma (2014)
    James Larkin, Paolo A. Ascierto et al. New England Journal of Medicine
  4. Expert and Novice Performance in Solving Physics Problems (1980)
    James Larkin, John McDermott et al. Science
  5. Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group (2012)
    Keith T. Flaherty, Caroline Robert et al. Zurich Open Repository and Archive (University of Zurich)
  6. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial (2018)
    F. Stephen Hodi, Vanna Chiarion‐Sileni et al. The Lancet Oncology
  7. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) (2017)
    Jacob Schachter, Antoni Ribas et al. The Lancet
  8. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma (2017)
    Jeffrey S. Weber, F. Stephen Hodi et al. Journal of Clinical Oncology
  9. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study (2019)
    Caroline Robert, Antoni Ribas et al. The Lancet Oncology
  10. Immune checkpoint inhibitors in melanoma (2021)
    Matteo S. Carlino, James Larkin et al. The Lancet
  11. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study (2019)
    Georgina V. Long, Reinhard Dummer et al. The Lancet Oncology
  12. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial (2015)
    Robert J. Motzer, Thomas E. Hutson et al. The Lancet Oncology
  13. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis (2017)
    Samra Turajlic, Kevin Litchfield et al. The Lancet Oncology
  14. Management of toxicities of immune checkpoint inhibitors (2016)
    Lavinia Spain, Stefan Diem et al. Cancer Treatment Reviews
  15. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up (2022)
    John B.A.G. Haanen, Michel Obéid et al. Annals of Oncology
  16. Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling (2015)
    Eishu Hirata, María Romina Girotti et al. Cancer Cell
  17. The First Measurement of Spectral Lines in a Short-Period Star Bound to the Galaxy’s Central Black Hole: A Paradox of Youth (2003)
    A. M. Ghez, Gaspard Duchêne et al. The Astrophysical Journal
  18. Immune checkpoint inhibitors and cardiovascular toxicity (2018)
    Alexander R. Lyon, Nadia Yousaf et al. The Lancet Oncology
  19. DETECTION AND CHARACTERIZATION OF EXOPLANETS AND DISKS USING PROJECTIONS ON KARHUNEN-LOÈVE EIGENIMAGES (2012)
    Rémi Soummer, Laurent Pueyo et al. The Astrophysical Journal Letters

Immediate Impact

68 by Nobel laureates 26 from Science/Nature 95 standout
Sub-graph 1 of 20

Citing Papers

Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
Immune checkpoint therapy—current perspectives and future directions
2023 StandoutNobel
41 intermediate papers

Works of James Larkin being referenced

Enhancing anti-tumour efficacy with immunotherapy combinations
2020
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
2017 Standout
and 31 more

Author Peers

Author Last Decade Papers Cites
James Larkin 18682 12541 7530 627 32.8k
Peter Ellis 9761 10594 6647 752 36.0k
Marc W. Kirschner 10447 65149 1124 394 88.4k
Leroy Hood 6745 42525 2857 721 74.4k
Richard Simon 8578 8356 6492 347 35.0k
Akira Suzuki 2975 13586 1900 960 31.8k
Jun S. Liu 3917 23227 3673 451 41.2k
Jianjun Liu 2094 6960 1180 1.1k 19.3k
Robert A. Gatenby 5040 10872 3372 321 25.8k
Michael Simons 3162 18334 2235 425 33.7k
C. M. S. Cohen 2251 3518 1285 602 16.3k

All Works

Loading papers...

Rankless by CCL
2026